Ivergelan

Ivermectin, the active ingredient in Ivergelan, is a macrocyclic lactone antiparasitic presented as an oral tablet for oral use. It is employed to treat a range of helminth and ectoparasite infections in adults and children as directed by a healthcare professional.

GNH USA supplies Ivergelan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, providing consistent quality, regulatory compliance and a reliable distribution network across multiple regions.

Ivergelan (ivermectin) is indicated for parasitic infections caused by nematodes and ectoparasites, helping to eliminate the organisms and reduce disease manifestations. - Onchocerciasis: reduces microfilarial load and helps prevent ocular and skin disease progression. - Strongyloidiasis: eradicates intestinal larvae, preventing chronic infection and hyperinfection syndrome. - Scabies: eliminates the Sarcoptes scabiei mite, relieving itching and skin lesions. - Lymphatic filariasis: decreases microfilariae in blood, contributing to transmission control. - Other helminth infections: provides broad‑spectrum activity against various intestinal and tissue‑dwelling worms.

Ivergelan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Mild skin rash: localized erythema or pruritus. - Nausea: transient feeling of queasiness. - Diarrhea: loose stools, usually self‑limiting. - Dizziness: light‑headed sensation, often resolves without intervention.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, hypotension, and rash. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurological manifestations: seizures, ataxia, or altered mental status.

Before prescribing Ivergelan, clinicians should consider several safety factors. - Pregnancy: safety not established; use only if benefits outweigh potential risks. - Breastfeeding: consult a healthcare provider; ivermectin may be excreted in breast milk. - Renal impairment: dose adjustment may be required; monitor renal function closely. - Concomitant CNS depressants: may enhance neurologic effects; observe the patient. - Drug interactions: review all current medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Ivergelan can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase ivermectin plasma concentrations. - Concurrent use with P‑glycoprotein inhibitors (e.g., verapamil) can raise systemic exposure. - Combination with other neurotoxic antiparasitics may potentiate neurotoxicity.

Moderate Interactions (Monitor Closely): - Concurrent use with warfarin may affect anticoagulation; monitor INR regularly. - Combination with other antiparasitic agents (e.g., albendazole) may increase the risk of adverse effects. - Use with macrolide antibiotics may modestly increase ivermectin levels; observe for side‑effects.